ARCHIMED acquires a majority stake in Arkstone
Forging a powerful partnership to accelerate global healthcare innovation and dominate the emerging AI-driven clinical decision support market
4 Aug 2025Industry news
Arkstone has been acquired by ARCHIMED, a leading private equity firm specializing in the healthcare sector. The transaction marks a pivotal moment in Arkstone’s growth trajectory, positioning the company to expand its global footprint, deepen its R&D capabilities, and bring its precision-guided technology to more clinicians around the world.
Backed by ARCHIMED’s capital, extensive healthcare expertise, and international reach, Arkstone is poised to scale its impact on the global fight against antimicrobial resistance (AMR), one of the most urgent public health threats of our time.
Arkstone’s flagship OneChoice Report leverages ML and AI to generate optimal infectious disease treatment recommendations by analyzing laboratory results alongside patient data, and delivers guidance to clinicians at the moment lab results are received. Already in use by laboratories across the United States and internationally, Arkstone is transforming how healthcare providers diagnose, treat, and understand infectious diseases.
Following the acquisition, Arkstone will continue to operate with its existing team. The company’s next phase will focus on rapid growth, further product development, and entry into new markets.
The partnership underscores the critical importance of antimicrobial stewardship and positions Arkstone as a global leader at the intersection of AI, infectious disease, and clinical decision support.
“Arkstone’s OneChoice Report is redefining infectious disease management. Our partnership will enable Arkstone to reach more markets, accelerate product innovation, and ultimately save lives by reducing the misuse of antibiotics,” said Igor Petricca, Partner at ARCHIMED. “This deal offers an additional dimension, as Clinical Decision Support software (CDS) and infectious disease are at the crossroads of hot subsectors of our Healthcare IT and Diagnostics franchises.”
“ARCHIMED’s acquisition of Arkstone supercharges our mission and opens new horizons for innovation and global reach,” said Ari Frenkel, MD, MPH, Chief Science Officer and Co-Founder of Arkstone. “This partnership ensures we have the resources, network, and strategic guidance to deliver our vision globally. Together, we’ll expand access to the tools clinicians need to combat antimicrobial resistance and prescribe responsibly.”